Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 7, 2015, Pages 1748-1753

  Narayana, Ashwath ^a   Manoharan, Aravind ^a   Narayan, Madhusudana Shampur ^b   Kalappa, Sudarshan Mysore ^c   Biligumba, Gangaboraiah ^a   Haradanahalli, Ravish ^a   Anand, Ashwini Manoor ^b  

^a KEMPEGOWDA INSTITUTE OF MEDICAL SCIENCES   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^c National Centre for Disease Control   (India)

Author keywords

Animal bite cases; Immunogenicity; Intradermal; One week 4 site regimen; Rabipur; Safety; Verorab

Indexed keywords

NEUTRALIZING ANTIBODY; RABIES IMMUNOGLOBULIN; RABIES VACCINE; IMMUNOGLOBULIN;

ADULT; ANTIBODY TITER; ARTICLE; BITE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOGENICITY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MYALGIA; OPEN STUDY; PAIN; PHASE 3 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RAPID FLUORESCENT FOCUS INHIBITION TEST; WORLD HEALTH ORGANIZATION; ANIMAL; BIOASSAY; BITES AND STINGS; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; HORSE; IMMUNIZATION; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; PATIENT SAFETY; POST EXPOSURE PROPHYLAXIS; RABIES; SOCIOECONOMICS;

ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; BITES AND STINGS; ENDPOINT DETERMINATION; FEMALE; HORSES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULINS; INJECTIONS, INTRADERMAL; MALE; PATIENT SAFETY; POST-EXPOSURE PROPHYLAXIS; RABIES; RABIES VACCINES; SOCIOECONOMIC FACTORS; WORLD HEALTH ORGANIZATION;

EID: 84944459132     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1048938     Document Type: Article

References (21)

1. WHO Expert Consultation on Rabies. Second report. Technical Report Series No. 982. Geneva: World Health Organization; 2013
2. World Health Organization (WHO). Rabies vaccines, WHO position paper. Weekly Epidemiological Record 2010; 32(85):309-20
3. WHO Expert Committee on Rabies. Eight report. Technical report series No. 824. Geneva: World Health Organization; 1992.
4. Wilde H. Failures of post-exposure rabies prophylaxis. Vaccine 2007; 25:7605-9; PMID:17905484; http://dx. doi. org/10. 1016/j. vaccine. 2007. 08. 054
5. Shantavasinkul P, Tantawichien T, Wilde H, Sawangvaree A, Kumchat A, Ruksaket N, Lohsoonthorn V, Khawplod P, Tantawichien T. Post exposure rabies Prophylaxis Completed in 1 Week: Preliminary Study. CID 2010; 50:56-60; PMID:19995217; http://dx. doi. org/10. 1086/649211
6. Human and dog rabies prevention and control. Report of the WHO/Bill & Melinda Gates foundation consultation. Annecy, France 7-9 October 2009.
7. Sudarshan MK, Ashwath Narayana DH, Madhusudana SN, Ramesh Holla, Ashwin YA, Gangaboraiah B, Ravish HS. Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis. Hum Vaccin Immunotherapeut 2012; 8(8):1077- 81; PMID:22699446; http://dx. doi. org/10. 4161/ hv. 20471
8. Warrell MJ, Nicholson KG, Warrell DA, Suntharasamai P, Chanthavanich P, Viravan C, Sinhaseni A, Chiewbambroongkiat MK, Pouradier-Duteil X, Xueref C, et al. Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 1985; 1(8437):1059-62; PMID:2860284
9. Suntharasamai P, Chaiprasithikul P, Wasi C, Supanaranond W, Auewarakul P, Chanthavanich P, Supapochana A, Areeraksa S, Chittamas S, Jittapalapongsa S, et al. A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for post exposure prophylaxis. Vaccine 1994; 12(6):508-12; PMID:8036824; http://dx. doi. org/10. 1016/0264- 410X(94)90308-5
10. Madhusudana SN, Premanand N, Ranjini S. Evaluation of two intradermal vaccination regimens using purified chick embryo cell vaccine for post-exposure prophylaxis of rabies. Nat Med J India 2001; 14 (3):145-7; PMID:11467142
11. Briggs DJ, Banzhoff A, Nicolay U, Dumavibhat B, Tongswas S, Wasi C. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified verocell rabies vaccine. Bulletin of the World Health Organization 2000; 78:683-7
12. Quiambao BP, Dimaano EF, Ambas C, Davis R, Banzhoff A, Malerczyk C. Reducing the cost of postexposure rabies prophylaxis: efficacy of PCEC rabies vaccine administered intradermally using the Thai Red Cross post-exposure regimen in patients severely exposed to laboratory confirmed rabies animals. Vaccine 2005; 23:1709-14; PMID:15705476; http://dx. doi. org/10. 1016/j. vaccine. 2004. 09. 027
13. Madhusudana SN, Sanjay TV, Mahendra BJ, Sudarshan MK, Ashwathnarayana DH, Anandgiri MS Muhamuda K, Ravi K, Vakil HB, Malerczyk C. Comparison of safety and immunogenecity of purified chick embryo cell vaccine and purified verocell rabies vaccine using the Thai Red Cross intradermal regimen at a dose of 0. 1 mL. Hum Vaccin 2006; 2(5):200-4.
14. Arvydas A, Alvydas L, Ligita B, Angelika B, Claudius M. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified verocell rabies vaccine (PVRV) in a four site intradermal schedule (4-0-2-0-1-1): An immunogenic, cost effective and practical regimen. Vaccine 2006; 24 (19):4116-21
15. Khawplod P, Wilde H, Sirikwin S, Benjawongkulchai M, Limusanno S, Jaijaroensab W, Chiraguna N, Supich C, Wangroongsarb Y, Sitprija V. Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection. Vaccine 2006; 24(16):3084-6; PMID:16494972; http://dx. doi. org/10. 1016/j. vaccine. 2006. 01. 051
16. Ravish HS, Veena V, Madhusudana SN, Sudarshan MK, Ashwath Narayana DH, Gangaboraiah, Ashwin BY, Rachana AR, Manjula S. Safety and Immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab N) administered intradermally as post exposure prophylaxis. Hum Vaccin 2014;10(8):2433-7
17. Sampath G, Madhusudana SN, Sudarshan MK, Ashwathnarayana DH, Mahendra BJ, Ullas TP, Mohan K, Madhusudhan SK, Ravish HS. Immunogenicity and safety study of Indirab: A verocell based chromatographically purified human rabies vaccine. Vaccine 2010; 28:4086-90; PMID:20403351; http://dx. doi. org/10. 1016/j. vaccine. 2010. 03. 064
18. Mahendra BJ, Harish BR, Vinay M. A study of factors influencing compliance of IDRV at ARC of Mandya Institute of Medical Sciences, Mandya. J APCRI 2009; 11(1):18-20
19. Katie Hampson, Sarah Cleaveland, Deborah Briggs. Evaluation of Cost-Effective Strategies for Rabies Post- Exposure Vaccination in Low-Income Countries. PLoS Neglect Trop Dis 2011; 5(3): e982; PMID:21408121; http://dx. doi. org/10. 1371/journal. pntd. 0000982
20. Ashwathnarayana DH, Madhusudana SN, Sampath G, Satapathy DM, Mankeshwar R, Ravish HS Ullas PT, Behra TR, Sudarshan MK, Gangaboraiah, et al. A comparative study on the safety and immunogenicity of purified duck embryo cell vaccine (PDEV, Vaxirab) with purified chick embryo cell rabies vaccine (PCEC, Rabipur) and purified vero cell rabies vaccine (PVRV, Verorab). Vaccine 2010; 28 (1):148-51; PMID:19818720; http://dx. doi. org/ 10. 1016/j. vaccine. 2009. 09. 090
21. Suwansrinon K, Wilde H, Benjavongkulchai M, Banjongkasaena U, Lertjarutorn S, Boonchang S, Suttisri R, Khowplod P, Daviratanasilpa S, Sitprija V. Survival of neutralizing antibody in previously rabies vaccinated subjects: A prospective study showing long lasting immunity. Vaccine 2006; 24:3878-80; PMID:16530893; http://dx. doi. org/ 10. 1016/j. vaccine. 2006. 02. 027